ACIP recommends RSV vaccination for adults 60 years and older in the United States

The Advisory Committee on Immunization Practices (ACIP) published a recommendation report for respiratory syncytial virus (RSV) vaccines in adults aged 60 years and older in the United States. This is not a primary research study but a formal recommendation based on ACIP's review of available evidence. The report does not specify which vaccine products are included, nor does it detail the comparator groups or clinical trial data that informed the decision.

No specific efficacy results, safety data, or absolute numbers from supporting studies are reported in this summary. Key outcomes such as vaccine effectiveness against RSV-associated lower respiratory tract disease, hospitalization rates, and mortality are not quantified here. The duration of protection and optimal timing for vaccination are also not specified.

The recommendation emphasizes the use of shared clinical decision-making between healthcare providers and patients in this age group. This approach suggests that vaccination should be considered based on an individual's risk factors for severe RSV disease and their personal values. The report does not discuss funding sources or potential conflicts of interest related to the recommendation.

As a recommendation report rather than primary evidence, clinicians should consult the full ACIP statement for complete guidance, including specific vaccine products, dosing schedules, and contraindications. The absence of reported efficacy and safety data in this summary limits direct clinical interpretation, requiring providers to seek the underlying evidence reviewed by the committee.